ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL404
CHEMBL404
Compound Name TAZOBACTAM
ChEMBL Synonyms Tazocillin | TAZOBACTAM SODIUM | TAZOBACTAM | YTR-830H | CL 307,579 | CL 298,741
Max Phase 4 (Approved)
Trade Names Tazocillin
Molecular Formula C10H12N4O5S

Additional synonyms for CHEMBL404 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES C[C@]1(Cn2ccnn2)[C@@H](N3[C@@H](CC3=O)S1(=O)=O)C(=O)O
Standard InChI InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6( ...
Download InChI
Standard InChI Key LPQZKKCYTLCDGQ-WEDXCCLWSA-N

Sources

  • BindingDB Database
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL404

Molecule Features

CHEMBL404 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Bacterial beta-lactamase TEM inhibitor Bacterial beta-lactamase TEM PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Cholecystitis, AcuteD041881EFO:1001289Cholecystitis, Acute3ClinicalTrials
Otitis MediaD010033EFO:0004992Otitis media1ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma3ClinicalTrials
SepsisD018805HP:0100806sepsis3ClinicalTrials
AbscessD000038EFO:0003030abscess3ClinicalTrials
InfectionD007239EFO:0000544infection3ClinicalTrials
ClinicalTrials
Pneumonia, BacterialD018410EFO:1001272bacterial pneumonia3ClinicalTrials
Shock, SepticD012772EFO:0006834septic shock3ClinicalTrials
Urinary Tract InfectionsD014552EFO:0003103urinary tract infection4DailyMed
Hematologic NeoplasmsD019337EFO:0001642lymphoid neoplasm3ClinicalTrials
OsteomyelitisD010019EFO:0003102osteomyelitis2ClinicalTrials
Intraabdominal InfectionsD0594134DailyMed
Diabetic FootD017719EFO:1001459diabetic foot3ClinicalTrials
PneumoniaD011014EFO:0003106pneumonia3ClinicalTrials
Pseudomonas InfectionsD011552EFO:0001076Pseudomonas infection3ClinicalTrials

Clinical Data

ClinicalTrials.gov TAZOBACTAM
The Cochrane Collaboration TAZOBACTAM

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL404. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2065 Beta-lactamase TEM Escherichia coli 1.000
CHEMBL2725 Beta-lactamase Enterobacter cloacae 1.000
CHEMBL5031 Beta-lactamase Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228) 1.000
CHEMBL5956 Beta-lactamase SHV-1 Escherichia coli 1.000

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2065 Beta-lactamase TEM Escherichia coli 1.000
CHEMBL4114 Beta-lactamase Staphylococcus aureus 1.000
CHEMBL2725 Beta-lactamase Enterobacter cloacae 1.000
CHEMBL5956 Beta-lactamase SHV-1 Escherichia coli 1.000
CHEMBL5031 Beta-lactamase Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228) 1.000
CHEMBL3499 Beta-lactamase class C Enterobacter cloacae 1.000
CHEMBL4840 Beta-lactamase type II Bacteroides fragilis 0.981

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
300.3 300.0528 -1.52 3 122.46 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 1 0 9 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
2.33 .85 .6 -3.13 1 20 0.67

Structural Alerts

There are 3 structural alerts for CHEMBL404. To view alerts please click here.

Compound Cross References

ATC J - ANTIINFECTIVES FOR SYSTEMIC USE
J01 - ANTIBACTERIALS FOR SYSTEMIC USE
J01C - BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01CG - Beta-lactamase inhibitors
J01CG02 - tazobactam

ChemSpider ChemSpider:LPQZKKCYTLCDGQ-WEDXCCLWSA-N
DailyMed tazobactam sodium
Wikipedia Tazobactam

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL404



ACToR 89786-04-9
BindingDB 50053173
Brenda 1226
ChEBI 9421
ChemicalBook CB7473784
DrugBank DB01606
DrugCentral 2572
eMolecules 2724829 36552982 29706580
EPA CompTox Dashboard DTXSID8023634
FDA SRS SE10G96M8W
Human Metabolome Database HMDB0015544
IBM Patent System 31B0395AB4AFE65C47645A12F6363B2E
KEGG Ligand C07771
LINCS LSM-5323
Mcule MCULE-7574505159
MolPort MolPort-002-500-123
Nikkaji J246.119F
PharmGKB PA164764504
PubChem 123630
PubChem: Thomson Pharma 14751709 16012340
SureChEMBL SCHEMBL122302
ZINC ZINC000003787060

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/LPQZKKCYTLCDGQ-WEDXCCLWSA-N spacer
spacer